Malignant Melanoma: Beyond the Basics.
Pavri SN, Clune J, Ariyan S, Narayan D.
Plast Reconstr Surg. 2016 Aug;138(2):330e-340e. doi: 10.1097/PRS.0000000000002367.
Unusual Clinical Presentations of Malignant Melanoma: A Review of Clinical and Histologic Features with Special Emphasis on Dermatoscopic Findings.
Cabrera R, Recule F.
Am J Clin Dermatol. 2018 Nov;19(Suppl 1):15-23. doi: 10.1007/s40257-018-0373-6.
[Malignant melanoma].
Lodde G, Zimmer L, Livingstone E, Schadendorf D, Ugurel S.
Pathologe. 2020 May;41(3):281-292. doi: 10.1007/s00292-020-00776-x.
[Malignant melanoma].
Lodde G, Zimmer L, Livingstone E, Schadendorf D, Ugurel S.
Hautarzt. 2020 Jan;71(1):63-77. doi: 10.1007/s00105-019-04514-0.
DNA hypermethylation is associated with invasive phenotype of malignant melanoma.
Koroknai V, Szász I, Hernandez-Vargas H, Fernandez-Jimenez N, Cuenin C, Herceg Z, Vízkeleti L, Ádány R, Ecsedi S, Balázs M.
Exp Dermatol. 2020 Jan;29(1):39-50. doi: 10.1111/exd.14047. Epub 2019 Nov 14.
Primary malignant melanoma.
Mısır AF, Durmuşlar MC, Zerener T, Gün BD.
Saudi Med J. 2016 Apr;37(4):446-9. doi: 10.15537/smj.2016.4.15017.
Management of Advanced Invasive Melanoma: New Strategies.
Villani A, Scalvenzi M, Micali G, Lacarrubba F, Fornaro L, Martora F, Potestio L.
Adv Ther. 2023 Aug;40(8):3381-3394. doi: 10.1007/s12325-023-02555-5. Epub 2023 Jun 12.
Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway.
Li CY, Wang Q, Wang X, Li G, Shen S, Wei X.
Eur J Pharmacol. 2019 Sep 5;858:172463. doi: 10.1016/j.ejphar.2019.172463. Epub 2019 Jun 15.
Malignant melanoma.
Lang PG Jr.
Med Clin North Am. 1998 Nov;82(6):1325-58. doi: 10.1016/s0025-7125(05)70418-1.
Clinical recognition of early invasive malignant melanoma.
MacKie RM.
BMJ. 1990 Nov 3;301(6759):1005-6. doi: 10.1136/bmj.301.6759.1005.
